GLOBAL ANTICOAGULANT REGISTRY IN THE FIELD – ATRIAL FIBRILLATION

GARFIELD-AF IS THE LARGEST ONGOING PROSPECTIVE REGISTRY IN AF PATIENTS

Over 57,000
NEWLY DIAGNOSED AF PATIENTS

From more than 1,000
CENTRES

Across 35
COUNTRIES

Based on real world data generated from over 57,000 patients collated between 2010 and 2018, GARFIELD-AF is yielding important new insights from multiple branches of enquiry:

- Collecting real world data on the impact of anticoagulant therapy in blood clot management
- Enhancing the breadth and depth of the understanding of stroke prevention in AF patients
- Converting insights to help develop strategies for improving patient outcomes worldwide

5 COHORTS
2-8 year follow-up data collection is ongoing

Insights on outcomes currently available for:

- 2-year 30,000 patients
- 1-year 40,000 patients

GARFIELD-AF is an independent academic research initiative, led by an international steering committee under the auspices of the Thrombosis Research Institute (TRI)

The GARFIELD-AF registry is funded by an unrestricted research grant from Bayer Pharma AG